GENEART AG will become part of the US-Based Biotechnology Company Life Technologies Corp.
Life Technologies acquires 58 % of GENEART shares via it´s German subsidiary Applied Biosystems Deutschland GmbH
Advertisement
The founders of GENEART AG Prof. Dr. Ralf Wagner, Prof. Dr. Hans Wolf, Dr. Marcus Graf, and individual members of the management as well as the venture capital companies EquiNet EarlyStage Capital and S-REFIT AG, have signed contracts with Applied Biosystems Deutschland GmbH for selling their GENEART shares.
Applied Biosystems Deutschland GmbH thus holds about 58% of GENEART AG shares and is planning a voluntary public tender offer for the remaining GENEART AG shares. Applied Biosystems Deutschland GmbH is the German subsidiary of Life Technologies Corporation, a California/US biotechnology company with 2009 revenues of 3.3B U.S. dollar and about 9,000 employees. Furthermore, a cooperation agreement between GENEART AG and Life Technologies has been concluded.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Settlement of patent infrigment lawsuit - QIAGEN pays Oxford Immunotec for royalty free license
Category:GAG_secreting_cells
Jury Finds In Favor Of Monsanto In Patent Case Involving Bayer CropScience And Insect-Protected Corn Technology

Hold the cream and sugar: black coffee linked to lower risk of death - Benefits diminished with additives
Wacker and MorphoSys expand Cooperation to use Wacker's ESETEC Technology for Production of Antigen Material

New microchip technology performs 1,000 chemical reactions at once - Technique may accelerate drug discovery for cancer, other diseases
